{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:42:32Z","timestamp":1784547752002,"version":"3.55.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014013","name":"United Kingdom Research and Innovation","doi-asserted-by":"publisher","award":["grant reference APP2033"],"award-info":[{"award-number":["grant reference APP2033"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010756","name":"Health and Social Care Research and Development Division","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010756","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Rare diseases are characterized by low prevalence, a profound impact on patients, and significant challenges in accessing treatment. In Saudi Arabia, the absence of an official definition hampers policymaking, resource allocation, and orphan drugs accessibility. This study aimed to address this gap by proposing a definition of rare diseases using inputs and views from a Saudi multi-stakeholder workshop.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A 1-day workshop was hosted in collaboration with the Saudi Health Council in Riyadh on 5 June 2023, involving 59 participants from various sectors, including clinicians, policymakers, patient advocates, and industry professionals. Using the Vevox<jats:sup>\u00ae<\/jats:sup> platform, participants engaged in structured activities comprising a demographic survey and 10 interactive voting sessions. Preferred qualitative and quantitative criteria for defining rare diseases were identified and analyzed using descriptive statistics and thematic and content analysis of open-ended questions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The findings indicated a strong preference (96%) for an integrated definition combining qualitative and quantitative criteria. Key qualitative terms such as \u201cDisease\u201d (62%), \u201cSerious\u201d (53%), and \u201cDisorder\u201d (51%) were favored for their clarity and broad applicability. \u201cGenetic\u201d etiology was preferred by 91% of participants, citing its relevance and data availability. Patient-centered criteria, including \u201clife-threatening\u201d (73%) and \u201cconsiderable reduction in quality of life\u201d (91%), were emphasized. Economic and resource-focused considerations, such as \u201cLack of Resources\u201d and \u201cCombined Efforts to Prevent\u201d (each at 60%), reflected key unmet needs in the current healthcare landscape. Among quantitative criteria, \u201cPrevalence\u201d (82%) emerged as the most accepted, aligned with international practices, although opinions were mixed on the inclusion of population size thresholds, underscoring the definitional complexity of defining RDs with both precision and flexibility.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This study provides a foundational basis and scientific root for defining rare diseases in the Saudi context, addressing key gaps in healthcare policies. By integrating evidence-based, patient-centered, and resource-oriented criteria, the proposed definition supports equitable access, improved patient care, and sustainable innovation, in alignment with Saudi Arabia\u2019s Vision 2030 goals. Further refinement with broader stakeholder inputs is essential for the successful integration of Saudi healthcare policies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1595967","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T12:55:22Z","timestamp":1752756922000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Shaping national rare diseases definition in Saudi Arabia: outcome from health ecosystem multisectoral workshop"],"prefix":"10.3389","volume":"16","author":[{"given":"Ghada Mohammed","family":"Abozaid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussain Abdulrahman","family":"Al-Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz","family":"Alrabiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiba","family":"Alomary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy Jayne","family":"McKnight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1583477","DOI":"10.3389\/fphar.2025.1583477","article-title":"Towards a sustainable rare disease and orphan drug ecosystem in Saudi Arabia: policy insights from a multi-stakeholder workshop","volume":"16","author":"Abozaid","year":"","journal-title":"Front. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e086527","DOI":"10.1136\/bmjopen-2024-086527","article-title":"Global insight into rare disease and orphan drug definitions: a systematic literature review","volume":"15","author":"Abozaid","year":"","journal-title":"BMJ Open"},{"key":"B3","doi-asserted-by":"publisher","first-page":"4732","DOI":"10.3390\/ijerph20064732","article-title":"Enhancing equitable access to rare disease diagnosis and treatment around the world: a review of evidence, policies, and challenges","volume":"20","author":"Adachi","year":"2023","journal-title":"Int. J. Environ. Res. public health"},{"key":"B4","doi-asserted-by":"publisher","first-page":"11786329221121214","DOI":"10.1177\/11786329221121214","article-title":"Healthcare transformation in Saudi Arabia: an overview since the launch of vision 2030","volume":"15","author":"Alasiri","year":"2022","journal-title":"Health Serv. insights"},{"key":"B5","doi-asserted-by":"publisher","first-page":"784","DOI":"10.26719\/2011.17.10.784","article-title":"Health care system in Saudi Arabia: an overview","volume":"17","author":"Almalki","year":"2011","journal-title":"East Mediterr. Health J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/13696998.2025.2506967","article-title":"A strategic framework for synergizing managed entry agreement efforts to access pharmaceutical products in saudi Arabia-results from a multi-stakeholder workshop","volume":"28","author":"Al-Omar","year":"2025","journal-title":"J. Med. Econ."},{"key":"B7","volume-title":"Exploring the integration of evidence-based medicine, quality of life considerations, and health economics for rare diseases","author":"Amrein","year":"2020"},{"key":"B8","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s40273-017-0514-4","article-title":"Defining and measuring the affordability of new medicines: a systematic review","volume":"35","author":"Anto\u00f1anzas","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"B9","doi-asserted-by":"publisher","first-page":"101738","DOI":"10.1016\/j.jsps.2023.101738","article-title":"Cross-national comparative study of orphan drug policies in Saudi Arabia, the United States, and the european union","volume":"31","author":"Balkhi","year":"2023","journal-title":"Saudi Pharm. J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"112962","DOI":"10.1136\/bmjebm-2024-112962","article-title":"Efforts towards the institutionalisation of evidence-informed decision-making","author":"Boeira","year":"2025","journal-title":"BMJ Evidence-Based Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology","volume":"3","author":"Braun","year":"2006","journal-title":"Qual. Res. Psychol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.jval.2020.06.020","article-title":"Access and unmet needs of orphan drugs in 194 countries and 6 areas: a global policy review with content analysis","volume":"23","author":"Chan","year":"2020","journal-title":"Value Health"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1028545","DOI":"10.3389\/fpubh.2022.1028545","article-title":"Rare disease emerging as a global public health priority","volume":"10","author":"Chung","year":"2022","journal-title":"Front. Public Health"},{"key":"B14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13023-015-0241-x","article-title":"A proposed definition of rare diseases for China: from the perspective of return on investment in new orphan drugs","volume":"10","author":"Cui","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/978-3-319-67144-4_20","article-title":"A global approach to rare diseases research and orphan products development: the international rare diseases research consortium (IRDiRC)","volume":"1031","author":"Cutillo","year":"2017","journal-title":"Rare Dis. Epidemiol. Update Overv."},{"key":"B16","doi-asserted-by":"publisher","first-page":"115119","DOI":"10.1016\/j.socscimed.2022.115119","article-title":"Market access for medicines treating rare diseases: association between specialised processes for orphan medicines and funding recommendations","volume":"306","author":"Fontrier","year":"2022","journal-title":"Soc. Sci. Med."},{"key":"B17","volume-title":"Saudi health council - kingdom of Saudi Arabia","year":"2023"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.2311.13729","article-title":"Comparison of pipeline, sequence-to-sequence, and GPT models for end-to-end relation extraction: experiments with the rare disease use-case","author":"Gupta","year":"2023","journal-title":"arXiv"},{"key":"B19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/d41573-019-00180-y","article-title":"How many rare diseases are there?","volume":"19","author":"Haendel","year":"2020","journal-title":"Nat. Rev. drug Discov."},{"key":"B20","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1093\/jlb\/lsy019","article-title":"Addressing the needs of Canadians with rare diseases: an evaluation of orphan drug incentives","volume":"5","author":"Harris","year":"2018","journal-title":"J. law Biosci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1186\/s13023-022-02498-0","article-title":"Rare diseases in Tanzania: a national call for action to address policy and urgent needs of individuals with rare diseases","volume":"17","author":"Kaywanga","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"B22","article-title":"Assessing access to innovative treatment: a prevalence-based cost-of-illness study","author":"Lekander","year":"2010","journal-title":"CiteSeerX"},{"key":"B23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.9734\/IJTDH\/2022\/v43i241373","article-title":"Current status and countermeasure of the research on rare diseases in China","volume":"10","author":"Ma","year":"2013","journal-title":"Life Sci. J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1007\/978-3-031-35529-5_92","article-title":"Artificial intelligence in drug discovery and development","author":"Mak","year":"2024","journal-title":"Drug Discov. Eval. Saf. Pharmacokinet. assays"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1017\/S0266462322000393","article-title":"Methods and criteria for the assessment of orphan drugs: a scoping review","volume":"38","author":"Mohammadshahi","year":"2022","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"B26","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.healthpol.2017.03.009","article-title":"HTA programme response to the challenges of dealing with orphan medicinal products: process evaluation in selected European countries","volume":"123","author":"Nicod","year":"2019","journal-title":"Health policy Amsterdam Neth."},{"key":"B27","volume-title":"Health sector transformation program delivery plan 2020-2021","author":"Program","year":"2021"},{"key":"B28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/b978-0-12-813695-9.00003-0","article-title":"Rare diseases: Genomics and public health","author":"Repetto","year":"2020","journal-title":"Appl. Genomics Public Health"},{"key":"B29","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.jval.2015.05.008","article-title":"Rare disease terminology and Definitions-A systematic global review: report of the ISPOR rare disease special interest group","volume":"18","author":"Richter","year":"2015","journal-title":"Value Health"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1016\/S0140-6736(08)60872-7","article-title":"Why rare diseases are an important medical and social issue","volume":"371","author":"Schieppati","year":"2008","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/QAI.0000000000001151","article-title":"Using CD4 data to estimate HIV incidence, prevalence, and percent of undiagnosed infections in the United States","volume":"74","author":"Song","year":"2017","journal-title":"J. Acquir Immune Defic. Syndr."},{"key":"B32","volume-title":"Application of an early HTA framework for determining potential cost-effectiveness and value of a medical device the case of the ably bed","author":"Straum","year":"2018"},{"key":"B33","doi-asserted-by":"publisher","first-page":"4510","DOI":"10.3390\/jcm13154510","article-title":"Navigating the unique challenges of caregiving for children with rare diseases: are the care experiences of all caregivers the same? A focus on life-limiting rare diseases","volume":"13","author":"Walkowiak","year":"2024","journal-title":"J. Clin. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s41669-021-00271-w","article-title":"Criteria and scoring functions used in multi-criteria decision analysis and value frameworks for the assessment of rare disease therapies: a systematic literature review","volume":"5","author":"Zelei","year":"2021","journal-title":"Pharmacoecon Open"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1595967\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T12:55:24Z","timestamp":1752756924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1595967\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":34,"alternative-id":["10.3389\/fphar.2025.1595967"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1595967","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]},"article-number":"1595967"}}